Literature DB >> 17373709

Recognition of Cdk2 by Cdk7.

Graziano Lolli1, Louise N Johnson.   

Abstract

Cdk7, a member of the cyclin dependent protein kinase family, regulates the activities of other Cdks through phosphorylation on their activation segment, and hence contributes to control of the eukaryotic cell cycle. Cdk7 is itself phosphorylated on the activation segment. Cdk7 phosphorylates Cdk1, Cdk2, Cdk4, and Cdk6, but only Cdk1 and Cdk2 can phosphorylate Cdk7 and none of them is able to auto-phosphorylate. The activation segments of the Cdks are very similar in sequence. Their specificity does not appear to be dictated by the sequences surrounding the phosphorylation sites but by structural determinants at remote sites. Through mutagenesis studies, we have identified regions in Cdk2 responsible for its interaction with Cdk7. A model has been built that explains the molecular basis for the specificity observed in Cdk recognition. The two kinases are arranged in a quasi-symmetric head-to-tail arrangement in which the N-terminal lobe from one kinase docks against the C-terminal lobe from the other kinase, and the activation segments are within reach of the opposite catalytic sites. Further experiments demonstrate that cyclin A hydrophobic pocket is not a recruitment site for Cdk7. 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17373709     DOI: 10.1002/prot.21370

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  12 in total

1.  The role of XPD in cell apoptosis and viability and its relationship with p53 and cdk2 in hepatoma cells.

Authors:  Hong-yun Wang; Gao-fei Xiong; Ji-xiang Zhang; Hong Xu; Wu-hua Guo; Jiang-jing Xu; Xiang-yang Xiong
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

2.  Depletion of Maternal Cyclin B3 Contributes to Zygotic Genome Activation in the Ciona Embryo.

Authors:  Nicholas Treen; Tyler Heist; Wei Wang; Michael Levine
Journal:  Curr Biol       Date:  2018-03-22       Impact factor: 10.834

3.  Regulation of Cdk7 activity through a phosphatidylinositol (3)-kinase/PKC-ι-mediated signaling cascade in glioblastoma.

Authors:  Shraddha R Desai; Prajit P Pillai; Rekha S Patel; Andrea N McCray; Hla Y Win-Piazza; Mildred E Acevedo-Duncan
Journal:  Carcinogenesis       Date:  2011-10-21       Impact factor: 4.944

4.  Putting one step before the other: distinct activation pathways for Cdk1 and Cdk2 bring order to the mammalian cell cycle.

Authors:  Karl A Merrick; Robert P Fisher
Journal:  Cell Cycle       Date:  2010-02-23       Impact factor: 4.534

5.  CDK7/GRP78 signaling axis contributes to tumor growth and metastasis in osteosarcoma.

Authors:  Tao Zhang; Jingjie Li; Mengkai Yang; Xinglong Ma; Zhuoying Wang; Xiaojun Ma; Mengxiong Sun; Wei Sun; Jing Xu; Yingqi Hua; Zhengdong Cai
Journal:  Oncogene       Date:  2022-08-30       Impact factor: 8.756

6.  Cell cycle-related kinase in carcinogenesis.

Authors:  Ye Tian; Han Wan; Guang Tan
Journal:  Oncol Lett       Date:  2012-07-27       Impact factor: 2.967

7.  Distinct activation pathways confer cyclin-binding specificity on Cdk1 and Cdk2 in human cells.

Authors:  Karl A Merrick; Stéphane Larochelle; Chao Zhang; Jasmina J Allen; Kevan M Shokat; Robert P Fisher
Journal:  Mol Cell       Date:  2008-12-05       Impact factor: 17.970

8.  Cryo-EM catalyzes the exploration of drug selectivity: The CDK7 inhibitor example.

Authors:  Montserrat Samsó
Journal:  Biophys J       Date:  2021-02-17       Impact factor: 4.033

9.  CDK4 T172 phosphorylation is central in a CDK7-dependent bidirectional CDK4/CDK2 interplay mediated by p21 phosphorylation at the restriction point.

Authors:  Xavier Bisteau; Sabine Paternot; Bianca Colleoni; Karin Ecker; Katia Coulonval; Philippe De Groote; Wim Declercq; Ludger Hengst; Pierre P Roger
Journal:  PLoS Genet       Date:  2013-05-30       Impact factor: 5.917

10.  Binding to DNA of the RNA-polymerase II C-terminal domain allows discrimination between Cdk7 and Cdk9 phosphorylation.

Authors:  Graziano Lolli
Journal:  Nucleic Acids Res       Date:  2009-01-09       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.